Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-11-0820
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Nectin-Like Molecule-4/Cell Adhesion Molecule 4 Inhibits the Ligand-Induced Dimerization of ErbB3 With ErbB2

Scientific Reports
Multidisciplinary
2017English

Activated Akt1 Accelerates MMTV-c-ErbB2 Mammary Tumourigenesis in Mice Without Activation of ErbB3

Breast Cancer Research
Cancer ResearchOncology
2008English

Zinc Finger Transcription Factors Designed for Bispecific Coregulation of ErbB2 and ErbB3 Receptors: Insights Into ErbB Receptor Biology

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2005English

Loss of Nrdp1 Enhances ErbB2/ErbB3-Dependent Breast Tumor Cell Growth

Cancer Research
Cancer ResearchOncology
2006English

Mutation of a SHC Binding Site Tyrosine Residue in ErbB3/HER3 Blocks Heregulin-Dependent Activation of Mitogen-Activated Protein Kinase

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1998English

Mechanisms for DNA‑damaging Agent‑induced Inactivation of ErbB2 and ErbB3 via the ERK and P38 Signaling Pathways

Oncology Letters
Cancer ResearchOncology
2017English

Specificity and Heregulin Regulation of Ebp1 (ErbB3 Binding Protein 1) Mediated Repression of Androgen Receptor Signalling

British Journal of Cancer
Cancer ResearchOncology
2004English

The Anti-erbB3 Antibody MM-121/SAR256212 in Combination With Trastuzumab Exerts Potent Antitumor Activity Against Trastuzumab-Resistant Breast Cancer Cells

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2013English

Driving Cancer Through ErbB3

Science-Business eXchange
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy